Jail-to-Community opioid treatment: monthly shot vs. daily pill

NCT ID NCT06306443

Recruiting now Disease control Sponsor: Friends Research Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a monthly extended-release buprenorphine injection works better than daily sublingual tablets for adults with opioid use disorder who are about to be released from jail. 240 participants will be randomly assigned to one of the two treatments while still incarcerated and followed for 12 months after release. The goal is to see which approach reduces opioid relapse and keeps people in treatment longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine (extended-release injection and sublingual tablet)
What this could lead to: If it works, this could show that a monthly injection of buprenorphine helps people leaving jail stay in treatment longer and avoid relapse better than daily tablets.
What could go wrong: This is a single open-label study with 240 participants, so results may not apply broadly. Both treatments are already approved, so the main question is which works better in this specific setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Baltimore Central Booking & Intake Center
RECRUITING

Baltimore, Maryland, 21202, United States
Friends Research Institute
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.